Category: JCN Newswire

Smaller "head" than the existing model, more efficient for handling subcompact mini vehicles・Domestic production allows for more focused after-sales service, as well as customization in a timely manner to meet customer needsTOKYO, Mar 4, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Machinery Systems (MHI-MS), a part of Mitsubishi Heavy Industries (MHI) Group, has finalized domestic development of an autonomous car and vehicle transportation and storage system (hereafter referred to as "a vehicle transport robot") to move automobiles autonomously, and has started trial operations and endurance tests at its production plant.MHI-MS launched a collaborative project in 2021 with its partner Stanley Robotics (SR), a French venture firm, with the intention of importing the robots from France and marketing them domestically. It was later decided to produce a domestic model with Japanese specifications, allowing for more focused after-sales service in Japan, as well as customization in a timely manner to meet customer needs. With the switch to a domestic production policy, MHI-MS is pursuing measures for domestic production, including submitting applications and registering core patents in Japan.(Note1) The Japan market model has a smaller "head" than the existing model, this makes smaller vehicles easier to handle. In addition, at the customer's request, MHI-MS provides a "dress-up service" where the exterior of the head can be customized based on the customer's preference.MHI-MS has established a network of about 100 maintenance and other service bases in Japan. This hub network can also be used to provide service for vehicle transport robots. The adoption of domestic production will allow MHI-MS to provide "Made in Japan" quality with prompt after-sales service.Utilizing these robots for automated transport of finished vehicles(Note2) will greatly improve the work environment for workers engaged in vehicle transport on a regular basis, even in bad weather, extreme heat, and other harsh environments, while also responding to the demands of the logistics industry such as DX (digital transformation) and efficiency improvement.For automated valet parking(Note3) at commercial facilities, the robot will park the car in a vacant space, making it possible to turn the distant parking spaces that people tend to avoid into "close" parking spaces. It also eliminates the problem of drivers being distracted while looking for a vacant space, and causing an accident due to inattention. Further, CO2 emissions from driving vehicles through the site are suppressed, contributing to the realization of a society that is friendly to both people and the planet.Going forward, MHI-MS, as a pioneer in vehicle transport robots in Japan, will combine this innovative technology with the advanced intelligent transportation systems including traffic flow control technology, unmanned system monitoring and EV operation management technology developed by MHI Group to provide services that meet a wide range of customer needs.(1) See the following press release regarding the domestic registration of core patents. www.mhi.com/jp/news/24091101.html (Japanese)(2) The system can operate 24 hours a day year-round in automobile factories, ports, motor pools, and other compounds where vehicles need to be moved, solving the problem of a shortage of skilled drivers while at the same time delivering safe transport at low cost.(3) When the driver stops at a designated berth close to the facility, instead of having to find a parking space on their own, the vehicle transport robot moves the vehicle to a vacant space, taking over parking on behalf of the driver. The process is reversed when retrieving the vehicle, with the robot transporting the vehicle back to the berth at the time specified by the driver in advance using the smartphone app. For drivers, there is no need to find a parking space or park, and no concerns about brushing against the adjacent car when opening the door. For more information on the demonstration test of automated valet parking conducted at a commercial facility in Japan, see the following press releases. www.mhi.com/news/220613.htmlhttps://www.mhi.com/news/221118.htmlAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., Mar 4, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia).In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision, proposing to the TGA the same apolipoprotein E4 (ApoE4) noncarrier and heterozygote indication that was agreed by the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA). In the course of the reconsideration of the initial decision, the TGA proposed an alternative narrow therapeutic indication only for ApoE4 noncarriers as an increasing number of ApoE4 alleles is a potential risk factor for ARIA. They did not agree that safety has been established for ApoE4 heterozygotes. Eisai proposed alternative indications, one of which was to maintain the ApoE4 noncarrier and heterozygote indication, but with heterozygotes treated in specialist centers and supervised by physicians with expertise in treatment of AD and monitoring for ARIA; however, the TGA rejected our proposal. “We are extremely disappointed and surprised by the TGA’s decision and understand that the AD community in Australia may also feel disheartened, especially given that eleven countries and regions across the globe have granted marketing authorization. We tried earnestly to reach a compromise with the TGA on an indication that would adequately represent the data in the application but were unfortunately unsuccessful at this time,” said Lynn Kramer, M.D., Chief Clinical Officer at Eisai. “The TGA proposed a narrow indication that would limit access to only ApoE4 noncarriers. This indication would deny approximately two-thirds (~70%) of all potentially eligible patients access to a treatment that could slow the progression of AD. Eisai believes ApoE4 heterozygote carriers should at least also have access to lecanemab given the similar benefit-risk profile to the noncarrier population. Therefore, we could not accept this restrictive indication as it is not patient-centric. Given this outcome, we are deeply concerned that Australians living with Alzheimer’s disease will not have access to a treatment that slows the progression of early Alzheimer’s disease by targeting its underlying causes. Eisai remains committed to ensuring eligible Australians with early Alzheimer’s disease can access lecanemab and is exploring options to achieve this, including potentially seeking review by the Administrative Review Tribunal.”In Australia, the number of people living with dementia was estimated to be approximately 411,000 in 2023, and is reported to increase to approximately 849,000 by 2058.1 AD is considered the most common cause of dementia, typically accounting for 60-70% of cases.2 AD progresses over time in stages with increasingly severe symptoms that greatly impact not only those who are living with AD, but also their loved ones, care partners and society. There is a significant unmet need for new treatment options that slow down the progression of AD from its early stage.=Aβ which is involved in the onset of AD, gradually aggregates in the brain 15 to 20 years before symptoms appear, eventually forming insoluble plaques, a pathological feature of AD. AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque removal.3,4,5 Only lecanemab works to fight AD in two ways: continuously clearing protofibrils* ,the most toxic Aβ species, and rapidly clearing plaque. This mechanism has been shown to reduce the rate of disease progression and to slow cognitive and functional decline. Lecanemab has been approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates, the United Kingdom, Mexico, Macau and Oman. Regulatory filings for the treatment have been made in the EU and 17 other countries and regions. In the EU, in February 2025, the Committee for Medicinal Products for Human Use reaffirmed its positive opinion for lecanemab in early AD, adopted in November 2024, and the European Commission is proceeding with the decision-making process for lecanemab’s marketing authorization.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.6Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.7About lecanemabLecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab is approved in the U.S.,8 Japan,9 China,10 South Korea,11 Hong Kong,12 Israel,13 the United Arab Emirates,14the United Kingdom,15 Mexico16, Macau and Oman. Eisai has submitted applications for approval of lecanemab in 17 countries and regions. In the EU, in February 2025, the Committee for Medicinal Products for Human Use reaffirmed its positive opinion for lecanemab in early AD, adopted in November 2024, and the European Commission is proceeding with the decision-making process for lecanemab’s marketing authorization. In January 2025, the supplemental Biologics License Application (sBLA) for intravenous (IV) maintenance dosing of the treatment was approved in the U.S. After an 18 months initiation phase with once every two weeks of dosing, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks or continuing 10 mg/kg once every two weeks may be considered. Additionally, the U.S. Food and Drug Administration (FDA) accepted Eisai’s Supplemental Biologics License (BLA) for the LEQEMBI subcutaneous autoinjector for weekly maintenance dosing in January 2025 and set a PDUFA action date for August 31, 2025.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (global and U.S), LinkedIn (for global, U.S.and EMEA) and Facebook (global).About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube Biogen Safe HarborThis news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.References(1) Dementia in Australia https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/population-health-impacts-of-dementia/prevalence-of-dementia(New Window)(2) World Health Organization. Dementia Fact Sheet. March 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/dementia(New Window).(3) Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease at Clinical Trials on Alzheimer's Disease (CTAD) conference. Available at: https://www.eisai.co.jp/news/2022/news202285.html(New Window)(4) van Dyck, H., et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 2023;388:9-21. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948(New Window).(5) Hampel H, Hardy J, Blennow K, et al. The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26(10):5481-5503.(6) Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z(7) Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.(8) U.S. Food and Drug Administration. 2023. FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. Last accessed: October 2024.(9) Reuters. 2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: October 2024.(10) The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi now approved in China. Last accessed: October 2024.(11) Pharmaceutical Technology. 2024. South Korea's MFDS approves Eisai-Biogen's LEQEMBI for Alzheimer's. Last accessed: October 2024.(12) Pharmaceutical Technology. 2024. Hong Kong approves Leqembi for Alzheimer's treatment. Last accessed: October 2024.(13) BioSpace. 2024. Leqembi approved for the treatment of Alzheimer's disease in Israel. Last accessed: October 2024.(14) United Arab Emirates Ministry of Health & Prevention. 2024. Registered Medical Product Directory. Leqembi. Last accessed: October 2024.(15) BioSpace. 2024. Leqembi authorized for early Alzheimer's disease in Great Britain. Last accessed: October 2024.(16) COFEPRIS authorizes innovative treatment for Alzheimer’s patients. Available at: https://bit.ly/3OKks6Y(New Window). Last accessed: December 2024.MEDIA CONTACTSEisaiEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.(UK, Europe, Australia, New Zealand and Russia)EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@eisai.comEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.(UK, Europe, Australia, New Zealand and Russia)EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@eisai.comBiogen Inc.Jack Cox+ 1-781-464-3260public.affairs@biogen.com Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, March 4, 2025 - (JCN Newswire via SeaPRwire.com) - Prideone Entertainment Co., Ltd. (Headquarters: Shibuya, Tokyo; CEO: Yasushi Akutagawa) has announced the concept for a new film tentatively titled "Fellers" to mark the 80th anniversary of the post-war era.Akutagawa said, "Fellers is an epic historical spectacle that looks behind the scenes of history from the perspective that it was an American officer, Bonner Fellers, and a group of Christians who saved the Emperor immediately after World War II."Akutagawa, who was the original planner and producer of the 2012 American-Japanese film Emperor (with a production budget of 3 billion yen), also focused on Bonner Fellers in that film. However, various interpretations were incorporated, and the final cut differed considerably from the original idea. The film became a love story between Bonner Fellers, played by Matthew Fox, and an imaginary Japanese lover.In response, various individuals, including Yoshiko Isshiki, former chairperson of Keisen Women's School, strongly suggested that a true-to-history depiction of Fellers be made in this 80th year since the end of the war. This led Akutagawa to create a new film from the fresh perspective. A Japanese director has been chosen for the project, and an original script based on historical facts has already been completed.Post-war Japan began on August 30, 1945, when General Douglas MacArthur, the Supreme Commander of the Allied Powers, landed in Japan and started the full-scale American occupation. MacArthur initiated mass arrests of war criminals and began activities to prosecute them. In the United States, there were strong calls from both the government and public to prosecute the Emperor. On the other hand, MacArthur considered the construction of an "anti-communist bulwark" in the Far East to be of utmost importance. He also eyed a future political career and a potential presidential run, so he felt that he needed to achieve success in post-war governance of Japan at all costs. From this viewpoint, he believed that arresting and executing the Emperor would gain him popular support. MacArthur ordered his subordinates to gather evidence that the Emperor had played a decisive role in Japan’s decision to go to war, including the attack on Pearl Harbor. Meanwhile, Bonner Fellers, an American officer with a deep knowledge of Japan, was tasked by MacArthur to investigate. Fellers, who had become acquainted with Yuri Isshiki before the war, was persuaded by the writings of Lafcadio Hearn, a renowned writer he was introduced to by Yuri, and believed that the Emperor should not be executed. Fellers immediately began searching for the whereabouts of Yuri and her mentor, Michi Kawai. This marked the beginning of a grand political drama and historical spectacle that would lay the foundations for what is now modern Japan. Had these events not unfolded as they did, Japan as we know it might not have existed.Currently, the project is progressing with filming planned for 2027 (in Japan and New Zealand) and release in the fall of 2028. Prideone Entertainment is forecasting a production budget of 4 billion yen, with an additional 1 billion yen for prints and advertising, and is seeking financing options.About the Producer and Executive Producer, Yasushi Akutagawa:Born April 3, 1956, in Kumamoto City, Kumamoto Prefecture. He graduated from the Film Department of the College of Art at Nihon University. Akutagawa started making 8mm films while attending Kumamoto Prefectural Seiseiko High School and decided to pursue a career in film production at university. After graduation, he worked at a major advertising agency before founding Prideone Entertainment Co., Ltd. Since then, he has been involved in producing a wide range of projects in film, television, theater, and radio.Notable Works:- 1991: Futari (Starring: Hikari Ishida) Directed by Nobuhiko Obayashi- 1995: Ashita (Starring: Kaori Takahashi, Yasufumi Hayashi) Directed by Nobuhiko Obayashi- 1998: Kaze no Uta ga Kikitai (Starring: Ryo Amamiya, Yuri Nakae, Tokyo International Film Festival Special Invitation) Directed by Nobuhiko Obayashi- 1999: Ano Natsu no Hi (Starring: Keiju Kobayashi, Yubari International Fantastic Film Festival Special Invitation) Directed by Nobuhiko Obayashi- 2000: Den'en no Ytsu (Starring: Tomokazu Miura, Mitsuko Baisho, Tokyo International Film Festival Special Invitation) Directed by Keisuke Kawahara- 2013: Emperor (Starring: Matthew Fox) Directed by Peter WebberFor inquiries:Prideone Entertainment Co., Ltd.https://yasushi-akutagawa.studio.site/PR: Tsukiokaakidiginfo@gmail.com Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Mar 5, 2025 - (JCN Newswire via SeaPRwire.com) - Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN® Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025. Sato Pharmaceutical and Eisai have concluded a new agreement, under which Eisai will carry out promotional activities for this drug and transfer operations to Sato Pharmaceutical during a transition period from April 1, 2025, to March 31, 2026.NAILIN® Capsules 100 mg have been marketed by Sato Pharmaceutical in Japan since July 2018, with a co-promotion agreement between both companies. However, following the conclusion of the co- promotion agreement and the signing of a new agreement, Sato Pharmaceutical will independently conduct promotions starting from April 2026, following a transition period. Additionally, inrelation to this matter, Sato Pharmaceutical will pay Eisai a lump sum.About fosravuconazoleFosravuconazole is a new oral antifungal component developed by Eisai. Fosravuconazole is a prodrug that improves thesolubility and bioavailability of ravuconazole, the main active ingredient. When administered to humans, it is rapidly converted toravuconazole. Ravuconazole demonstrates antifungal activity by inhibiting ergosterol biosynthesis, a membrane component of fungal cells.In Japan, Seren Pharmaceuticals Inc., which was granted exclusive development and commercialization of this drug by Eisai, has been advancing its development for onychomycosis with Sato Pharmaceutical. Sato Pharmaceutical obtained manufacturing and marketing approval in January 2018, and since July 2018, it has been marketed as Nailin Capsule 100mg.Sato Pharmaceutical and Eisai entered into a license agreement in July 2024, under which Sato Pharmaceutical will undertake the development and commercialization in Asia and Oceania* for fungal diseases.*10 ASEAN member states, Australia, New Zealand, South Korea, TaiwanMedia InquiriesEisai Co., Ltd.Public Relations Department TEL: +81 (0)3-3817-5120Sato Pharmaceutical Co., Ltd. Public Relations Department TEL: +81-(0)3-5412-7354 Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Mar 3, 2025 - (JCN Newswire via SeaPRwire.com) - NTT Corporation (NTT) and NTT DOCOMO, INC. announced today that they have successfully demonstrated the effectiveness and feasibility of In-Network Computing (INC),*1 an architecture that integrates and coordinates computing resources for services such as AI and mobile networks to enable end-to-end quality control, ensuring low latency and bandwidth usage. The demonstration was based on the “Inclusive Core”*2 concept for the 6G/IOWN era originally announced by NTT Corporation in a press release issued in October 2023.During this demonstration, the GSMA-defined Open Gateway*3 / CAMARA API*4 was utilized to develop and implement technologies for controlling network routing based on mobile network conditions. Additionally, new technologies were developed and implemented that enable connection and coordinated control between user communication devices and servers positioned near the user. These will allow on-demand computing services to be provided according to user needs. As a result, the demonstration confirmed that quality requirements spanning both network and computing domains can be rapidly achieved through API control based on user requests. Application of the INC architecture in real-time video data transmission and AI analysis showed that it could achieve accuracy of 90%, which is the AI model's performance limit.This proof of concept was conducted in collaboration with Nokia Corporation. The results will be showcased at Nokia's booth during Mobile World Congress Barcelona 2025, being held from March 3 to 6, 2025, where it will be presented as an example of next-generation network architecture.1. BackgroundDiscussions on international standardization for 6G networks are underway among various countries and organizations. 3GPP, a standardization body in which leading global telecom operators, network vendors and research institutions are participating, plans to commence the development of technical specifications such as architecture and protocols this year. Among the anticipated 6G use cases are new services such as immersive XR, artificial intelligence / machine learning, and sensing. To deliver these services without compromising performance, 6G-era networks will need to accelerate not only conventional communication processes but also the data processing of applications.In response to these challenges, and in the context of international standardization discussions, NTT and DOCOMO, along with many other companies, are considering INC as a core network technology to support 6G-era services. Another key feature of INC is its capability to facilitate the use of 6G services even on simplified devices, by supporting computational processing within the network.2. ISAP*5 OverviewNTT and DOCOMO are dedicated to the research and development of ISAP as the base platform for INC. ISAP is a platform that integrates with mobile networks to deliver computing services, and features the following technical characteristics:- It allows the configuring of computing services in response to each device's mobile network connection status.- It adapts computing services based on changes in cloud-based service usage.- It enables the controlling of computing functions in line with the operational state and attributes of both the mobile network and cloud-based services.3. INC architecture and expansion of existing architecture specificationsTraditionally, mobile networks have focused on managing device connectivity and mobility, primarily handling lower-layer connections from user terminals, through the mobile communication system, to external networks. However, with the evolution and expansion of high-performance services such as XR and edge computing, there is growing demand for higher-layer or application-specific requirements in mobile networks, a trend that is expected to become even more pronounced in the 6G era. Against this backdrop, NTT and DOCOMO have proposed an INC architecture that integrates computing functions into the User Plane Function (UPF).*6 Using an API to interface with core network control, NTT and DOCOMO explored methods to simultaneously set up computing functions and control device network connectivity, identifying necessary specification enhancements.The proposed architecture has three highlights:1. It derives and resolves control policies for communication and computation based on a service attributes and requirements profiles provided via an API.2. It coordinates slicing and communication quality control aligned with the activation of computing functions on the UPF.3. It adds the capability to configure communication sessions and computing features in the control interface for the UPF.4. Proof of Concept OverviewThe proof of concept was conducted by deploying 3GPP-compliant mobile core network on Amazon Web Services (AWS). This network was managed under Nokia's product, a Network as Code platform designed for API management and routing, as defined in GSMA Open Gateway and Linux Foundation CAMARA projects. Within this mobile core network, a new control function was introduced to handle the mobile core network, enabling it to configure communication routes to the ISAP platform in response to computing service activation requests received via the Network as Code platform. An integrated control mechanism was implemented on a container platform equipped with accelerators*7 such as DPUs and GPUs. This mechanism simultaneously activates both communication and computing services when a computing service startup request is issued.During the demonstration, the team verified that mobile connectivity can be provided in response to CAMARA API-based computing service startup requests, confirming the feasibility of on-demand computing services for mobile devices in a practical setting. Additionally, an AI-powered video analysis application was operated within this environment and by linking the computing services with the mobile network to reduce data exchange latency and jitter between devices and servers, it was confirmed that the accuracy rate—57% under conventional architectures—improved to 90%, reaching the performance limit of the AI model.5. Role of each companyNTT: Conducts overall architecture and system design and plans the demonstration, researches and prototypes the Inclusive Core and ISAP, and provides on-premise / cloud demonstration environments.NTT DOCOMO, INC.: Leverages its expertise in global standard specifications for mobile communication systems and leads discussions on methods for mobile network quality and routing control in this demonstration.Nokia Corporation: Offers 3GPP-compliant Core SaaS on the cloud and provides the Network as Code API management platform, compliant with GSMA Open Gateway and CAMARA.6. OutlookNTT and DOCOMO will continue to explore In-Network Computing capabilities with the aim of enabling computing services that work seamlessly with mobile networks in the 6G era. This will involve progressing technical studies and the implementation of solutions requiring high stability and low latency. Going forward, in partnership with Nokia, NTT and DOCOMO plan to expand their collaboration with telecom operators, network equipment and device manufacturers, cloud providers, and service operators. The goal is to advance INC research and development in order to facilitate service deployment, while also contributing to global standardization discussions scheduled for this year, including those led by 3GPP covering 6G architecture this year.(1) A technical concept whereby application-layer processing is delegated to data transfer functions within the network. This approach reduces latency and device power consumption, while delivering high-performance, feature-rich services. By offloading information processing to network-based devices such as switches, it also alleviates the load on terminals.(2) A network architecture proposed by NTT for the 6G/IOWN era. It enables various forms of convergence and cooperation over the network, thereby facilitating the fusion of computing and networking required by next-generation use cases such as AI-integrated communications and cyber-physical systems. For more details, refer to New windowhttps://www.rd.ntt/ns/inclusivecore/whitepaper_ver1.html (only available in Japanese)(3) A GSMA project aimed at establishing common carrier APIs for exposing carrier network functionalities. As of 2024, 62 mobile network operators are participating, working toward the global commercialization of these emerging carrier APIs.(4) An open-source project under the Linux Foundation that develops common carrier API specifications, enabling applications developers to access carrier network function worldwide regardless of region or operator.(5) As an In-Network Computing platform, ISAP intermediates the information processing required by services running on terminals and in the cloud. By rapidly synchronizing and coordinating both, it orchestrates a cascading processing environment on network-based hardware that is tailored to each communication context and service environment. This enables users to enjoy flexible service experiences without being limited by their devices or network conditions and allows service providers to reach a broader user base.(6) A component of the 5G network that handles data transfer, traffic routing, and other related functions.(7) Refers to hardware or software that enhances computing performance. In this demonstration, “accelerators” specifically refer to hardware accelerators such as Data Processing Units (DPUs) and Graphics Processing Units (GPUs).About NTTNTT contributes to a sustainable society through the power of innovation. We are a leading global technology company providing services to consumers and businesses as a mobile operator, infrastructure, networks, applications, and consulting provider. Our offerings include digital business consulting, managed application services, workplace and cloud solutions, data center and edge computing, all supported by our deep global industry expertise. We are over $93B in revenue and 330,000 employees, with $3.6B in annual R&D investments. Our operations span across 80+ countries and regions, allowing us to serve clients in over 190 of them. We serve over 75% of Fortune Global 100 companies, thousands of other enterprise and government clients and millions of consumers.About NTT DOCOMONTT DOCOMO, Japan's leading mobile operator with over 90 million subscribers, is one of the global leaders in 3G, 4G and 5G mobile network technologies. Under the slogan “Bridging Worlds for Wonder & Happiness,” DOCOMO is actively collaborating with global partners to expand its business scope from mobile services to comprehensive solutions, aiming to deliver unsurpassed value and drive innovation in technology and communications, ultimately to support positive change and advancement in global society.https://www.docomo.ne.jp/english/ Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Mar 3, 2025 - (JCN Newswire via SeaPRwire.com) - Space Compass and NTT DOCOMO, INC. jointly announced today that they have successfully completed data connectivity tests between the LTE base station and smartphones using high-altitude platform stations (HAPS)(1) from the stratosphere (altitudes of around 20km) in Laikipia County, Kenya.In this test, a communication demonstration using LTE was carried out between the HAPS flying at altitudes around 20km and 4G device on the ground. The LTE base station was connected to the ground gateway station(2), and a relay technology called non-regenerative relay(3) was used to reflect the radio waves through the communication device mounted on the HAPS flying in the stratosphere and connected to the ground based 4G device on the ground. As a result, a throughput of more than 4.66 Mbps was observed during reception of the radio wave transmitted from the ground gateway station to the 4G device via HAPS (Forward Link).The technology to stabilize the beam center to provide the connectivity coverage at a certain position toward a fixed point on the ground from the HAPS rotating in the stratosphere was implemented. Successful delivery of the reflected radio waves to the 4G equipment was confirmed at the test site in Kenya. This is the world's first successful establishment of wireless communication between a fixed-wing HAPS flying in the stratosphere at altitudes above 18 km and a smartphone on the ground.The fixed-wing HAPS aircraft Zephyr, which is designed, manufactured and operated by AALTO HAPS Limited ("AALTO"), a subsidiary of Airbus Defence and Space, was used for the testing. Zephyr has advanced aviation technology, having achieved a record for the longest flight of HAPS in 2022, with a continuous duration of 64 days.Based on the results obtained through test activities, Space Compass and NTT DOCOMO will continue to work towards our HAPS service's targeted entry-into service in 2026, and research and develop a space-based radio access network (RAN) as an NTN, with HAPS serving as key components to support ultra-wide mobile communication services in air, sea and space.The project is part of the Innovative ICT Fund Projects for Beyond 5G/6G, known as Beyond 5G, established by the National Institute of Information and Communications Technology (NICT), which envisions a society where connectivity is assured over the air, sea, and space regardless of user location. (JPJ012368C07702)Takaaki Sato, Senior Executive Vice President and Representative Member of the Board of Directors of NTT DOCOMO, said: "We are delighted about the successful connectivity test of HAPS in Kenya. This achievement marks a significant step forward in shaping the future of mobile communications. By combining long-duration stratospheric flights with DOCOMO's wireless technology, we aim to not only enhance disaster response and expand coverage areas but also to accelerate the delivery of innovative HAPS services that offer unprecedented value."Shigehiro Hori, Co-Chief Executive Officer of Space Compass Corporation, commented: "We are dedicated to working towards the commercialization of our HAPS service in 2026, and the success of this trial marks a significant step forward in achieving this goal. With this important milestone, we will continue to conduct testing and accelerate the development of our HAPS service. We are confident that the future of HAPS holds great potential, and we invite everyone to look forward to what's to come."Hughes Boulnois, Chief Executive Officer of AALTO, said: "This connectivity demonstration is a world-first for HAPS that underpins the capabilities of Zephyr when operating in the stratosphere. Alongside NTT DOCOMO and Space Compass, we have created a strong and complementary partnership that will pave the way for commercial services to begin in the stratosphere from 2026. We are now working with our Japanese partners in accelerating the roadmap for our technology development and services, utilising Zephyr as a game-changing platform for connectivity and Earth observation."(1) Abbreviation for High-Altitude Platform Station. It refers to an unmanned aerial vehicle capable of flying in the stratosphere at an altitude of about 20 km for a few days to several months without landing. The platform is equipped with relay devices, and it can cover areas with a diameter of 100 to 200 km (depending on the design of the aircraft). This technology is being explored for areas that have been difficult to cover, such as the air and seas, as well as rural and mountainous regions where are not economically viable for coverage.(2) A ground station which relays communication between the HAPS and the terrestrial communication network.(3) A communication system where the base station equipment is installed on the ground rather than onboard the HAPS, and the communication device (payload) on the HAPS acts as a relay, reflecting signals received from the ground. In contrast, when base station equipment is installed on the HAPS, it is called a regenerative relay system.About Space Compass CorporationSpace Compass is a joint venture company between NTT, Japanese Information and Communications Technology (ICT) leader, and SKY Perfect JSAT Corporation, Asia's largest satellite operator. We will launch a Space Integrated Computing Network to aid the realization of a sustainable society. For more information, visit our corporate website, https://space-compass.com/en/This project is one of the initiatives of space business brand under NTT Group's "NTT C89" and SKY Perfect JSAT's "JSAT".About NTT DOCOMONTT DOCOMO, Japan's leading mobile operator with over 90 million subscribers, is one of the global leaders in 3G, 4G and 5G mobile network technologies.Under the slogan "Bridging Worlds for Wonder & Happiness," DOCOMO is actively collaborating with global partners to expand its business scope from mobile services to comprehensive solutions, aiming to deliver unsurpassed value and drive innovation in technology and communications, ultimately to support positive change and advancement in global society.https://www.docomo.ne.jp/english/ Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Mar 3, 2025 - (JCN Newswire via SeaPRwire.com) - TOPPAN Inc. and NTT DOCOMO, Inc. announced today that they have signed a basic agreement that will allow them to jointly develop groundbreaking communication services for the forthcoming 6G era.TOPPAN is drawing on its expertise in information processing and computer graphics to deliver a wide variety of metaverse services. Concurrently, DOCOMO is spearheading development of next-generation communication technologies with its FEEL TECH platform, designed to extend human sensory experiences through networks, offering entirely new value for the 6G era.Under the terms of this agreement, TOPPAN will integrate its metaverse and advanced expression capabilities with DOCOMO's FEEL TECH platform. The two companies will subsequently collaborate in the development and provision of services in the fields of education, skill transmission, and online shopping.The first step in the process will be the integration of FEEL TECH with TOPPAN's metaverse app Metapa, which features educational content for museums designed for interactive learning. Development discussions will commence in April 2025. By incorporating FEEL TECH's sensory sharing capabilities into Metapa, both companies aim to develop next-generation content that will allow users to experience the texture of materials and tactile sensations of artists, enhancing art education through direct interaction.Going forward, TOPPAN and DOCOMO will remain dedicated to advancing efforts to deliver next-generation services that surprise and delight customers, using FEEL TECH. Copyright 2025 JCN Newswire via SeaPRwire.com.

Kawasaki and Tokyo, Mar 3, 2025 - (JCN Newswire via SeaPRwire.com) - Rakuten Mobile, Japan’s newest and most modern mobile network, today announced it will begin deploying base stations utilizing radio units (RU) developed by Fujitsu Limited, as it accelerates the expansion of its 5G (Sub6) network area in 2025.Leveraging its expertise in building a fully virtualized, cloud-native mobile network based on Open RAN standards in Japan, Rakuten Mobile will continue to rapidly deploy 5G Sub6 base stations and expand its coverage area. Fujitsu, through its compact and energy-efficient RU, will support Rakuten Mobile’s rollout of 5G commercial services and contribute to the further global adoption of Open RAN.The RU model to be used by Rakuten Mobile, 44R21, adopts the O-RAN specifications established by the O-RAN ALLIANCE – a worldwide community promoting the development of Open RAN specifications. The RU facilitates communication between the base station's distributed unit (DU) and centralized unit (CU) via a fronthaul interface (1). It has a proven track record of interoperability with equipment from various domestic and international vendors, enabling telecommunications carriers to diversify their equipment choices and mitigate supply chain risks. Additionally, using Fujitsu’s proprietary technology, the radio units are designed to be compact, lightweight and energy-efficient, thereby contributing to leaner space requirements and lower network operation costs.The RU 44R21 base model will be showcased at MWC Barcelona 2025, the world’s largest connectivity exhibition, held in Barcelona, Spain, from March 3 to 6, 2025.Going forward, Rakuten Mobile will use its pioneering virtualization network technology and existing base station infrastructure to reduce lead times from construction to operation, ensuring cost-efficient deployments of base stations. Additionally, Rakuten Symphony will work together with Fujitsu to discuss future collaborations, aiming to drive the global rollout of these units and accelerate the worldwide adoption of Open RAN technology.Sharad Sriwastawa, co-CEO and CTO of Rakuten Mobile, commented, "We are excited to partner with Fujitsu to accelerate the rollout of high-performance, energy-efficient 5G base stations. This collaboration will enable us to deliver exceptional mobile services to even more of our customers."Masaaki Moribayashi, Corporate Executive Officer and SEVP, Network Business and Special Assignment of Fujitsu Limited, commented, "Fujitsu’s focus has been to develop an innovative wireless platform that is compact, lightweight, and energy-efficient. In addition to this wireless device that complies with O-RAN standard specifications, Fujitsu will support Rakuten Mobile in building a flexible and efficient network, leveraging its extensive experience in O-RAN connectivity."(1) Fronthaul refers to the network that connects the control equipment and radio units that make up a base station.Product names, service names, and other names mentioned in this press release are generally trademarks or registered trademarks of their respective companies. Trademark symbols such as (TM) and (R) may be omitted in this press release.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.About Rakuten MobileRakuten Mobile, Inc. is a Rakuten Group company responsible for mobile communications, centered on its mobile network operator (MNO) business. Through continuous innovation and the deployment of advanced technology, Rakuten Mobile aims to redefine expectations in the mobile communications industry in order to provide appealing and convenient services for diverse customer needs.Press ContactsRakuten Mobile, Inc.Corporate Communications DepartmentE-mail: global-pr@mail.rakuten.comFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2025 JCN Newswire via SeaPRwire.com.

KAWASAKI, Japan, Mar 3, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced the launch of the Fujitsu Network 1FINITY™ P300 800G ZR/ZR+ coherent pluggable transceiver, an open, high-performance and sustainable key component for optical networking solutions. The transceivers, globally available from the second half of 2025, are compatible with third-party routers, Fujitsu’s Edge Networking portfolio, or in 1FINITY T-series transponder applications, offering flexible deployment options to optimize performance, cost, and power consumption according to the needs of network owners.Featuring the latest 3nm digital signal processor (DSP) semiconductor technology, in addition to pluggable support built-in to the Virtuora® network control solution, the transceivers enable high-performance operation with 30% power per bit reduction and lower costs versus previous pluggable generations. Being made in Japan, the P300 800G coherent pluggable offers high-quality precision components and supply chain resiliency. Compliant with open optical networking standards OIF ZR and Open ROADM MSA, the P-series portfolio will offer a future evolution path to data rates of 1.6 terabits per second (Tbps) and beyond.The 1FINITY P300 will be exhibited at the Fujitsu booth at MWC Barcelona 2025, the world's largest connectivity exhibition, held in Barcelona, Spain, from March 3rd to 6th and at OFC 2025 in San Francisco, California from April 1st to 3rd, 2025.With a majority of today’s businesses relying on Artificial Intelligence (AI) and cloud workloads, rising data demands are driving the need for greater speed, capacity and flexibility throughout telecommunications and data center networks. The 1FINITY P300 enables next-generation data center interconnect (DCI), metro, regional, and long-haul transport network owners to address these challenges sustainably and cost-effectively. Fujitsu’s new P-series coherent pluggables are the latest addition to the 1FINITY Ultra Optical System, a hyper-reliable optical portfolio delivering extreme performance and scalability, including currently available 400G ZR/ZR+ pluggable offerings.The 1FINITY P300 is equipped with ECC (Error Checking and Correcting) to automatically correct memory errors and other issues. Additionally, it features two firmware modules for redundancy, allowing continuous operation by switching to the backup firmware in case of a failure.When combined with the Virtuora Network Control portfolio, the 1FINITY P300 host element simplifies the planning, design, and deployment of multi-domain, multi-vendor optical and packet-optical networks, including IPoDWDM. Featuring industry-leading open optical control, design, and automation, it offers an end-to-end network management solution. Future updates to the Virtuora Network Control portfolio will also include pluggable management capabilities for use with third-party routers that support open optical networking. Virtuora software streamlines operational complexity, reduces time to issue resolution, and enhances both network availability and profitability.Fujitsu’s Commitment to the Sustainable Development Goals (SDGs)The Sustainable Development Goals (SDGs) adopted by the United Nations in 2015 represent a set of common goals to be achieved worldwide by 2030.Fujitsu’s purpose — “to make the world more sustainable by building trust in society through innovation” — is a promise to contribute to the vision of a better future empowered by the SDGs.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., Mar 3, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Aβ monoclonal antibody lecanemab, adopted in November 2024.(1) Following CHMP’s reaffirmation, after having considered the additional information requested by the European Commission (EC), the EC will resume the decision-making process for lecanemab's marketing authorization.In January 2025, as part of its decision-making process, the EC asked the CHMP to consider information on the safety of lecanemab that became available after the adoption of the CHMP opinion in November 2024 and whether this may require anupdate of the opinion, and to consider whether the wording of the risk minimization measures in the opinion is clear enough to ensure correct implementation. After reviewing the additional information, the CHMP concluded that its positive opinion for lecanemab does not need to be updated.Mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and AD dementia currently affects an estimated 15.2 million and 6.9 million people in Europe, respectively.(2) AD progresses over time in stages with increasingly severe symptoms that greatlyimpact not only those who are living with AD, but also their loved ones, care partners and society. There is a significant unmet need for new treatment options that slow down the progression of AD from its early stage.If the EC approves the lecanemab marketing authorization application, the approval will apply to all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway. Eisai and Biogen will continue to make every effort to deliver lecanemab to patients with early AD in Europe as soon as possible.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision- making authority.About lecanemab (generic name, brand name: Leqembi®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab has been approved in the U.S.,(3) Japan,(4) China,(5) South Korea,(6) Hong Kong,(7) Israel,(8) the United Arab Emirates,(9) the United Kingdom,(10) Mexico,(11) Macau and Oman, and is under regulatory review in 17 countries and regions including theEU. In January 2025, the U.S. Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application (sBLA) for once every four weeks maintenance dosing. In January 2025, the submission of a Biologics License Application (BLA) for maintenance dosing of a subcutaneous injection formulation, which is being developed to enhance convenience for patients, was accepted in the U.S.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School ofMedicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of ADtreatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase thebenefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim toeffectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn. About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.Biogen Safe HarborThis news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward- looking statements may beaccompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,”“expect,” “forecast,” “goal,” “guidance,” “hope,”“intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinicaltrials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assurethat any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that thesestatements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long- term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products,sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implementour corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk thatpositive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinicaltrials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arisefrom additional data or analysis obtained during clinical trials, regulatory authorities may require additional information orfurther studies, or may fail to approve or may delay approval of our drug candidates;the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risksand uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matterscan be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.(1) Committee for Medicinal Products for Human Use. 2024. Leqembi (Lecanemab).Overview. Available at: www.ema.europa.eu/en/medicines/human/EPAR/leqembi#overview Last accessed: January 2025(2) Gustavsson, A., et al. Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimer’s & Dementia.2023;19:658-670. https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12694. (3) U.S. Food and Drug Administration. 2023. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval. Last accessed: January 2025.(4) Reuters. 2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: January 2025.(5) The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi now approved in China. Last accessed: January 2025.(6) Pharmaceutical Technology. 2024. South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s. Last accessed: January 2025.(7) Pharmaceutical Technology. 2024. Hong Kong approves Leqembi for Alzheimer’s treatment. Last accessed: January 2025.(8) Pharmaceutical Business Review. 2024. Leqembi gains approval for Alzheimer’s treatment in Israel. Last accessed: January 2025.(9) United Arab Emirates Ministry of Health & Prevention. 2024. Registered Medical Product Directory. Leqembi. Last accessed: January 2025.(10) Lecanemab United Kingdom Summary of Product Characteristics. Available at: www.medicines.org.uk/emc/product/15908. Last accessed: January 2025.(11) The Pharma Letter. 2024. BRIEF-Mexican approval for Alzheimer’s drug Leqembi. Available at: www.thepharmaletter.com/brief-mexican-approval-for-alzheimers-drug-leqembi. Last accessed: January 2025.MEDIA CONTACTSEisai Co., Ltd.Public Relations Department TEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Jack Cox+ 1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations Department TEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com Copyright 2025 JCN Newswire via SeaPRwire.com.

KAWASAKI, Japan, Feb 28, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu's Oyama plant, home to its photonics product manufacturing and management division, has achieved a perfect score of 100 (Class A-Excellent) in a supply chain CSR audit conducted by the Joint Alliance for CSR (JAC), demonstrating Fujitsu's strict adherence to global CSR standards across all audit items (labor, safety and health, environment, business ethics, and management systems). Of the 123 companies audited on their record in 2023, only 18% achieved a Class A-Excellent rating of 90 points or higher. This audit was conducted by NTT, a member of JAC, in the presence of KDDI and SoftBank.This perfect score is a reflection of the various distinctive initiatives that Fujitsu’s Oyama plant has implemented. In health and safety, the plant regularly shares natural disaster situation reports and conducts employee training across departments. The photonics manufacturing division maintains a zero accident record as of today, and has logged over 10 million accident-free hours since 2018 (1). Environmentally, the plant participates in the Oyama City Zero Carbon & Nature Positive Promotion Platform, encouraging collaboration with the local authority towards decarbonization, coexistence with nature and in the implementation of energy-saving measures at the manufacturing site. Additionally, at its Oyama plant, Fujitsu manufactures the high-performance 1FINITY Ultra Optical System, which achieves world-leading long-distance transmission of 1.2 terabits per second. It is the world’s-first optical transmission device to use a water-cooling system, which reduces CO2 emissions by 60% compared to previous Fujitsu products.The Fujitsu Group will continue to promote sustainability management, provide sustainable value to JAC member carriers and CSR-conscious customers, and support the global business expansion of its customers.(1) Counted until January 20, 2025About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press Contacts:Fujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Feb 28, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. announced today that the company has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast growth factor (FGF) receptor selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, Japan brand name: TASFYGO®, “tasurgratinib”) in the Greater China region (mainland China, Hong Kong, Macau, and Taiwan, “licensed regions”) to a subsidiary of SciClone Pharmaceuticals (Holdings) Limited (Headquarters: Shanghai, China, “SciClone”). Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched.Under the terms of this agreement, Eisai will receive a contractual upfront payment. Additionally, Eisai will receive milestone payments based on the progress of development and regulatory approval, as well as sales milestone payments and certain royalties based on sales revenue after the product launch.Tasurgratinib is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against FGFR1, FGFR2 and FGFR3. Tasurgratinib was approved in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy. The medicine was launched in Japan in November 2024. A Phase I clinical trial (ClinicalTrials.gov, NCT04572295(New Window)) is underway in Japan for patients with estrogen receptor-positive and HER2-negative breast cancer.SciClone is a global biopharmaceutical company with an integrated platform for the development and commercialization of innovative therapies for cancer and severe infection, and a strong presence in the Greater China region. Through the conclusion of this agreement, Eisai expects to maximize the value of tasurgratinib in licensed regions, ensuring the earliest possible contribution to patients in need of the medicine.About SciClone PharmaceuticalsStaying true to its original aspiration of “SciClone gives life hope”, SciClone Pharmaceuticals is dedicated to improving patients’ health by providing top-tier healthcare products and services with global standards of care. SciClone Pharmaceuticals has established a product portfolio with differentiated advantages, including a number of first-in-class and best-in-class potential products / pipelines.For more information regarding SciClone Pharmaceuticals, please visit: www.sciclone.com and https://www.eisai.com/news/2025/pdf/enews202512pdf.pdf. Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Feb 28, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) has developed vRAN that supports the interfaces and components newly specified by the O-RAN Alliance for enhancing the security of Open vRAN. The NEC vRAN platform is now being used to verify the performance of SecureRAN (*) provided by CTOne, a subsidiary of Trend Micro, which also supports the specifications of the O-RAN Alliance.As cyberattacks targeting infrastructure providers and others become more sophisticated, measures to address security risks are becoming increasingly important. Open vRAN allows a variety of networks to be applied according to the deployment scenario of the telecommunications carrier, and while it offers a high degree of flexibility, it also requires measures to address threats to the network.In response to this, NEC is aiming to build and operate a safer and more secure network through the introduction and verification of SecureRAN for highly secure and flexible vRAN infrastructure.SecureRAN deploymentSecureRAN constantly references the latest threat information, and by responding immediately to vulnerabilities, it achieves advanced network monitoring and defense that covers the entire application layer of vRAN.NEC has been a member of the O-RAN Alliance since its inception, and has made important contributions to its activities for network openness and standardization.Specifically, NEC has developed highly secure Open vRAN by leveraging its expertise in conventional RAN construction, while also incorporating the O-RAN Alliance's interface components.Going forward, in order to further enhance the security of vRAN, NEC will verify the introduction of SecureRAN, with the aim of strengthening network infrastructure for customers and providing a safe and secure communications base.In addition, through the implementation of these verification tests, NEC will expand its support menu (introduction support, maintenance, operation support, etc.) for the commercial introduction of SecureRAN.(*)SecureRANSecureRAN is an O-RAN security solution developed and provided by CTOne, a subsidiary of Trend Micro. SecureRAN is designed to improve the effectiveness of security measures and ensure sustainable system deployment, providing robust security protection for critical O-RAN assets and AI-driven applications. https://tinyurl.com/3bckm8ry About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2025 JCN Newswire via SeaPRwire.com.

Mazda Motor Corporation's production and sales results for January 2025 are summarized below.I. Production1. Domestic ProductionMazda's domestic production volume in January 2025 increased 22.6% year on year due to increased production of passenger vehicles.[Domestic production of key models in January 2025]CX-5:25,266 units(down 2.0% year on year)MAZDA3:8,479 units(up 33.5%)CX-30:6,571 units(up 6.8%)2. Overseas ProductionMazda's overseas production volume in January 2025 increased 6.4% year on year due to increased production of passenger vehicles.[Overseas production of key models in January 2025]CX-30:14,079 units(down 1.3% year on year)CX-50:10,059 units(up 39.6%)MAZDA3:4,916 units(down 40.3%)II. Domestic SalesMazda's domestic sales volume in January 2025 increased 23.9% year on year due to increased sales of passenger vehicles.Mazda's registered vehicle market share was 4.1% (up 0.8 points year on year), with a 2.4% share of the micro-mini segment (down 0.4 points), and a 3.4% total market share (up 0.3 points).[Domestic sales of key models in January 2025]CX-5:2,339 units(up 116.4% year on year)MAZDA2:2,120 units(up 31.0%)CX-80:1,253 units III. ExportsMazda's export volume in January 2025 increased 14.3% year on year due to increased shipments to North America and other regions.[Exports of key models in January 2025]CX-5:21,848 units(down 4.8% year on year)MAZDA3:6,820 units(up 48.4%)CX-90:5,644 units(up 225.3%)IV. Global SalesMazda's global sales volume in January 2025 increased 1.5% year on year due to increased sales in the U.S., Japan, and other regions.[Global sales of key models in January 2025]CX-5:26,949 units(up 1.0% year on year)CX-30:17,465 units(down 0.3%)MAZDA3:13,090 units(down 28.0%)* Overseas production figures indicate Mazda-brand units coming off the production line (excluding CKD units).* Global production figures are the sum total of domestic and overseas production volumes.* All information in this press release is as of the release date. No updates after that date are reflected. Copyright 2025 JCN Newswire via SeaPRwire.com.

Toyota City, Japan, Feb 27, 2025 - (JCN Newswire via SeaPRwire.com) - Toyota Motor Corporation (Toyota) has announced that it has submitted a progress report on measures to prevent recurrence of model certification application issues to the Ministry of Land, Infrastructure, Transport and Tourism (MLIT) today in light of the correction order the ministry issued on July 31. This report, summarizing actions taken to date, is the second of a series of quarterly reports.Specific progress of recurrence prevention measuresWith the three pillars of "Strengthening Foundations," "Monozukuri," and "Human Development," Toyota has been promoting a review of the structure and system to ensure that each employee is aware of legal compliance and is able to do the job correctly. The company is also promoting onsite management, in which management goes to the genba and promptly takes appropriate action in response to abnormalities.The following concrete actions are being promoted across the Group with set priorities and activity plans.Strengthening FoundationsManagement visiting the operational genba to identify problems and make immediate decisions on how to deal with them.Management grasping staff hardships and efforts at the genba and discussing what it should do at weekly executive-level meetings related to certification.Enhancing internal controls by reinforcing abnormality management in the vehicle development process, strengthening certification operations audits by in-house inspectors, and introducing secondary audits of the abnormality management and auditing operations themselves.Checking the actual genba conditions of certification-related departments, allocating human resources and testing equipment to the Regulations and Certification Department and the Collision Testing Fields, etc.MonozukuriImplemented a new operational approach to ongoing development projects, incorporating measures to prevent recurrence in October 2024.Introduced a system to check the impact on certification operations at each milestone and make management decisions on the impact on certification operations, including the applicable laws and regulations, the scale of certification operations, the certification schedule, and the number of vehicles to be certified, for all vehicle development projects. (As of February 2025, a total of 35 such projects are being conducted.)Implemented discussions on countermeasures for worksite issues 10 times since previous report (22 times in total), reporting to the Board of Directors as appropriate. This system is ongoing.Human DevelopmentExpanding communication between management and employees to include not only development and certification, but also planning, production, sales and other certification-related worksites.Implemented regular communication through messages from the president (total of 14 times).Since February last year, Toyota Chairman Akio Toyoda, who is responsible for the Group, took the lead in calling on Group companies to start Toyota's company-wide TPS training program for Certification Work. The aim of this initiative is to create a better work system through improvement. The president and other members of management are on-site daily at various genba, such as planning, development, design, production, and sales, which are connected to the certification process. This is being done to clarify stagnation factors in each process and to create a system to identify abnormalities.Toyota will continue to make company-wide efforts to prevent the recurrence of certification issues to once again gain the trust of stakeholders. Copyright 2025 JCN Newswire via SeaPRwire.com.

HIROSHIMA, Japan, Feb 27, 2025 - (JCN Newswire via SeaPRwire.com) - Mazda Motor Corporation (Mazda) has announced that it conducted a demonstration operation of a cupola melting furnace (cupola), the core casting facility installed at its Hiroshima Plant, by fully replacing fossil fuels that emit CO2 during combustion with bio-coal briquettes, a biomass fuel derived from coconut shells, and confirmed the stable operation.The operation of a cupola that uses biomass fuel 100% has not been confirmed for social implementation in the world, and the company took on the challenge of conducting the demonstration experiment in collaboration with the foundry industry and local partners. In the future, Mazda will expand the circle of regional cooperation and promote an energy circulation scheme for local production for local consumption, aiming for carbon neutral (CN) operation of cupolas using waste-derived biomass fuels such as bio-coal briquettes by fiscal year 2030.Mazda has been promoting various initiatives to achieve CN at its global plants by 2035 based on the three pillars of "energy conservation," "shifting to renewable energies," and "introducing CN fuels, etc.," with the goal of achieving CN throughout its entire supply chain by 2050.Stable domestic procurement of raw materials is essential for a full conversion to biomass fuels which is in line with "introducing CN fuels," as one of the aforementioned initiatives. In March 2023, Mazda established the Cupola CN Co-creation Working Group by inviting volunteer companies and organizations to conduct research and development for the shift to biomass fuels, the establishment of production methods, and studies on the local procurement of raw materials. While bio-coal briquettes derived from coconut shells were used in the demonstration experiment this time, Mazda has been working to establish a locally produced, locally consumed energy circulation scheme in Hiroshima and neighboring areas, from biomass waste collection to production, with the aim of revitalizing local industries and contributing to the local communities. As part of such activities, Mazda has been collecting spent coffee bean husks from Tully's Coffee Shop*1 (operated by Tully's Coffee Japan Co., Ltd.) and vending machines*2 in the premises of Mazda Headquarters since November 2024, and confirmed through demonstration experiments that it is possible to produce bio-coal briquettes from these bean husks.Going forward, the company will work together with the local community to develop the local production for local consumption energy circulation scheme into a cooperative effort among industry, government, academia, and the private sector to realize stable raw material procurement of and implementation of fuel conversion.Mazda, together with the local communities, will steadily advance its challenge toward the achievement of CN throughout the supply chain in 2050, and contribute to the creation of an affluent society.For inquiries about biomass raw materials and fuel conversion technology for cupola:cupola-cn-info@mazda.co.jp Powertrain Engineering Dept., Production Engineering Div.For media inquiries, please contact below:mazda_hpr@mazda.co.jp Media Relations Dept., Mazda Motor Corporation(1) Franchisee: CULE Co., Ltd., Franchiser: Tully's Coffee Japan Co., Ltd. (2) Operated by Apex West Japan Co., Ltd. Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Feb 27, 2025 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. today announced that the company has been selected for the CDP’s “2024 Climate Change A List” for the second consecutive year. The CDP is an international non-profit organization that facilitates environmental information disclosure, and Honda was selected based on its initiatives in the areas of climate change and environmental transparency. The CDP is a not-for-profit charity that runs the global disclosure system for companies and local governments (cities, states and regions) around the world. The companies and local governments disclose their environmental information using the CDP questionnaire with three separate sectors – climate change, forest and water security. In 2024, more than 24,800 companies, including listed companies that account for more than 66% of global market capitalization, disclosed their environmental information. The CDP assesses the disclosed information on a score of A to D -, and companies with outstanding initiatives are named to the A List. Among more than 24,800 companies which disclosed environmental information for 2024, Honda was included in the short list of the companies making the A List.Honda is aiming to realize carbon neutrality for all products and corporate activities Honda is involved in by 2050. To this end, Honda has been pursuing electrification of its products by setting and disclosing 2030 milestone targets for both the sales ratio of electrified products and the reduction rate of CO2 emissions intensity during product use for motorcycles, automobiles and power products, respectively. In the area of corporate activities, Honda has set and disclosed a target to reduce the total amount of CO2 emissions by 46% from its corporate activities by 2030 compared to the FY2020 level. Working toward this target, Honda has been improving production efficiency, introducing various energy-saving measures, shifting toward the use of low-carbon energy and facilitating the utilization of renewable energy. Honda views these initiatives as leading to the selection of Honda to the Climate Change A list.Honda will strive to realize a carbon-neutral society, while continuing to take a proactive approach to the initiatives to address climate change and the disclosure of its environmental information. Copyright 2025 JCN Newswire via SeaPRwire.com.

Mitsubishi Heavy Industries Australia, Pty. Ltd. (MHI-AUS), the Australian subsidiary of Mitsubishi Heavy Industries, Ltd. (MHI), is expanding its business activities in Canberra to focus on providing support for the country's next general purpose frigate program and to strengthen its business network with related agencies and companies.MHI-AUS will prioritize measures to respond to requests from the Australian government in a timely manner, including providing flexible sales support, gathering information, and conveying information related to MHI products and services. The Japanese government is fully supportive of MHI's involvement in this project.In addition, as defense equipment and technology cooperation between Japan and Australia is progressing, MHI-AUS will promote mutual understanding and cooperation between Mitsubishi Heavy Industries and Australian defense industrial partners to contribute to strengthening Japan-Australia defense cooperation.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2025 JCN Newswire via SeaPRwire.com.

As part of its corporate governance reform, NEC Corporation (NEC; TSE: 6701) shifted to a Company with a Nominating Committee, etc. in fiscal 2023, and has been promoting the separation of oversight and execution and the clarification of the roles of each. In order to further strengthen the monitoring function of the Board of Directors from fiscal 2025, NEC has established a policy to strengthen corporate governance, focusing on the Board structure, CEO succession planning, and the remuneration system.Through this, NEC aims to further increase the transparency and objectivity of management, accelerate business growth, achieve the Mid-term Management Plan 2025, and sustainably enhance corporate value.1. Achieving a compact structure for the Board of DirectorsIn order to further invigorate discussions on medium- to long-term management policies and strategies at Board of Directors meetings, NEC will shift to a more optimal Board structure that is both sufficiently compact and has the necessary career experience and expertise in specialist fields, while also ensuring diversity.(1) Appointment of Independent Outside DirectorsOutside directors are selected for their skills and experience, which contribute to the sustainable growth of the corporate value of the company and enable the status of execution to be appropriately monitored. After the appointment, outside directors are also subject to peer review as part of the evaluation of effectiveness of the Board of Directors each year, and decisions on reappointment or dismissal are made based on the results of this review. However, the number of times they can be reappointed is limited to eight times.(2) Appointment of Inside DirectorsInside directors are selected from representatives of the execution side where substantial authority has been delegated from the Board of Directors. NEC aims to have the optimal structure for a Board of Directors as a Company with a Nominating Committee, etc., by having a minimum number of inside directors, centering on the CEO.2. CEO succession planning and the approach to developing and selecting the management team on the executive sideIn order to continuously and fairly appoint a CEO who will lead the sustainable enhancement of the company's global corporate value, the Nominating Committee and the CEO will work together to implement CEO succession planning while ensuring transparency and objectivity. In addition, the CEO will develop and appoint the necessary personnel for the management team that leads the business based on the company's medium- to long-term strategies.(1) The role of the Nominating Committee and CEO in CEO succession planningThe Nominating Committee is responsible for "determining the appropriate time for CEO succession" and "identifying candidates for the next CEO." It also supports the development of the next generation of management talent by the CEO. In addition, the CEO is responsible for "developing candidates for the next CEO" and "proposing candidates for succession to the Nominating Committee."(2) CEO term of office, decision on reappointment or dismissalIn order for the Nominating Committee to determine the appropriate timing for CEO succession, the CEO's term of office is not fixed. Instead, the Nominating Committee conducts an "evaluation review" each year and determines whether the CEO will be reappointed or dismissed in the following year based on the CEO's intentions, business performance, a 360-degree evaluation of the CEO, as well as the status of the development of the next CEO candidate.(3) Requirements for the next CEO candidateThe Nominating Committee will assess the candidates proposed by the CEO for the CEO successor from the perspective of their necessary management qualities and character as the next CEO, such as "transformational leadership," "vision and communication skills," "sense of responsibility and determination," "development and formation of an optimal management team," "ability to continue learning," and "ethics," and will select them in consideration of the medium-term management plan, management policies, and management environment.(4) Development and appointment of a management team to lead businessWith regard to Corporate Senior Executive Vice President, Corporate Executive Vice President, and Corporate Senior Vice President, including Executive Officers, NEC has been making decisions on reappointment and dismissal on a position-by-position basis every year from the perspective of "the right time, the right place, the right person." From April 2025 onwards, in order to accelerate flexible appointments of executives, including promoting young talent, ensuring diversity, as well as promotions, demotions and reappointments, NEC will thoroughly develop management talent and promote generational change by setting a maximum of three reappointments to the same position as a guideline.3. How remuneration systems should be structured to provide incentives for enhancing corporate valueNEC will establish an executive remuneration system that provides incentives for competing and winning against global competitors, with the aim of enhancing corporate value through the achievement of the Mid-term Management Plan 2025 and the next Mid-term Management Plan, which aims for even greater heights.Specifically, NEC aims to set competitive and superior remuneration levels in line with its growth and to increase the ratio of stock compensation in particular, thereby linking management to a constant awareness of corporate value. To accelerate this movement, NEC will expand its stock compensation system.(1) Introduction of stock compensation for Outside DirectorsIn order to further enhance the sharing of value with shareholders and strengthen awareness of the need for continuous enhancement in corporate value, NEC will introduce a non-performance-based, Restricted Stock Remuneration Plan for outside directors from June 2025.(2) Expansion of stock compensation for Executive Officers and othersIn order to strengthen the sharing of value with shareholders and to secure excellent human resources to take on management roles, in addition to the current performance-based stock compensation, a new non-performance-based Board Incentive Plan Trust will be introduced from April 2025 for Corporate Senior Vice President and above, including Executive Officers and others, and the ratio of stock compensation will be increased.Comment from Harufumi Mochizuki, Chairman of the Nominating CommitteeAs NEC looks to enhance its corporate value on a global scale, the transition to a company with a Nominating Committee etc. was a catalyst for us to discuss the ideal structure for a Board of Directors that will lead to continuous growth in corporate value and the development of the next generation of management for true growth. The selection of directors and support for the development of the next generation of management, including the next CEO, is an important role of the Nominating Committee, and we will continue to operate in a way that contributes to enhancing corporate value.Comment from Masashi Oka, Chairman of the Compensation CommitteeIn addition to achieving the goals of the Mid-term Management Plan 2025, the Compensation Committee has been discussing the direction and form of executive compensation that will serve as an incentive to achieve a competitive advantage globally over the medium to long term during the next Mid-term Management Plan period. As a result, NEC will introduce stock compensation for outside directors and increase the ratio of stock-based compensation for Officers from fiscal 2025, accelerating the strengthening of awareness of sustainable enhancement of corporate value. In addition, NEC will continue to strengthen the design and operation of its remuneration to ensure that it functions as an incentive to enhance corporate value and to secure promising management talent.About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2025 JCN Newswire via SeaPRwire.com.

SINGAPORE, Feb 26, 2025 - (JCN Newswire via SeaPRwire.com) - Olympus Corporation of Asia Pacific Limited (Olympus APAC), the regional headquarters of Olympus Corporation in Asia and Oceania, today announced a milestone for its iTind™ device with expanded availability across major markets in the Asia-Pacific (APAC) region, a move in line with its commitment and purpose of making people’s lives healthier, safer and more fulfilling.iTindAlready marketed in the United States and Europe, the iTind procedure is a minimally invasive solution for the treatment of benign prostatic hyperplasia (BPH), also known as an enlarged prostate. With a launch in Korea scheduled in March, iTind will become available in six1 markets across APAC.“With our upcoming launch in Korea, achieving wider availability of the iTind device in APAC is an important milestone for physicians and patients in our region. We’re excited to provide increased access to a minimally invasive outpatient BPH procedure for suitable patients, addressing a common health problem for men over 50 with the risk of BPH increasing with age. Symptoms of BPH include frequent urination with a sense of urgency and a weak urinary stream and excessive urination at night. The iTind procedure provides a rapid and effective patient-focused treatment option, with the added benefit of the procedure being able to be performed in a clinic room under local anaesthesia, helping ease pressure on hospital capacity.” said Daisuke Goto, Head of Surgical Business at Olympus APAC.As part of the roll-out of the iTind device across the region, Olympus has designed a comprehensive training programme to support Physicians and to maximise the success of incorporating the iTind procedure as part of their clinical practice.Olympus will continue its efforts to accelerate market development of the iTind minimally invasive BPH solution, providing more patients and physicians with access to this novel procedure, strengthening the care pathway and elevating the standard of care for patients with BPH.About iTindThe iTind, a temporarily implantable nitinol device, supports the relief of lower urinary tract symptoms (LUTS) secondary to BPH, offers a minimally invasive alternative for BPH treatment without the need for medications, permanent implants, or tissue removal. This innovative approach provides a short-term treatment option that reshapes the prostatic urethra and improves patient quality of life. In September 2023, the iTind procedure was included in the American Urological Association (AUA) clinical practice guideline for management of LUTS attributed to BPH. In the United States, two new Category I CPT codes2 for the iTind procedure went into effect January 1, 2025, which enable billing for the procedure at all sites of services.1 Thailand, Australia, Hong Kong, Singapore, India, Korea2 Current Procedural Terminology (CPT) code is a numeric code that identifies a medical procedure or service maintained by American Medical Association (AMA). Healthcare professionals use CPT codes to bill for medical services. About OlympusAt Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global X account: @Olympus_Corp.Media contact:Mail: Global-Public_Relations@olympus.comOlympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com Copyright 2025 JCN Newswire via SeaPRwire.com.